The post XRP ETFs Approval Countdown Continues With Key Clarification Made appeared on BitcoinEthereumNews.com. Key clarification made When XRP ETFs? XRP ETFs countdown remains on for October, with the SEC expected to reveal its decision on six ETF applications. This week saw a government shutdown as U.S. lawmakers failed to strike a deal on federal funding. As a result, the SEC missed a few deadlines on spot ETF decisions, prompting speculation on what comes next in the markets. The SEC is expected to rule on Grayscale XRP ETF (Oct. 18), 21Shares core XRP Trust ETF (Oct. 19), Bitwise XRP ETF (Oct. 22), Canary Capital XRP ETF (Oct. 23), WisdomTree XRP ETF (Oct. 24) and CoinShares XRP ETF (Oct. 23). The last government shutdown in late 2018 lasted 35 days, the longest in history. Given this, it is difficult to say for how long the current shutdown might last, prompting speculation in the XRP community on the implications if the XRP ETF deadlines were missed by the SEC. Key clarification made Crypto reporter Eleanor Terrett responded to a tweet by XRP enthusiast Chad Steingraber, who cited that the Teucrium XRP ETF was not approved by the SEC directly. This is because the deadline was reached and the SEC didn’t “approve or deny” the listing, adding that it was automatically allowed and that the SEC’s silence indicated compliance. Adding some context here for those asking if this applies to all ETFs, including the spots. The short answer is no. The Teucrium $XRP ETF holds Treasuries, cash, and swap receivables, so it was registered under the 40 Act, meaning the @SECGov didn’t need to actively approve it,… https://t.co/H8EiXVcOHp — Eleanor Terrett (@EleanorTerrett) October 3, 2025 Terrett added context on whether the instance of the Teucrium XRP ETF applies to all ETFs, including the spot ETF applications, to which she answered “no.” The Teucrium XRP ETF, according to… The post XRP ETFs Approval Countdown Continues With Key Clarification Made appeared on BitcoinEthereumNews.com. Key clarification made When XRP ETFs? XRP ETFs countdown remains on for October, with the SEC expected to reveal its decision on six ETF applications. This week saw a government shutdown as U.S. lawmakers failed to strike a deal on federal funding. As a result, the SEC missed a few deadlines on spot ETF decisions, prompting speculation on what comes next in the markets. The SEC is expected to rule on Grayscale XRP ETF (Oct. 18), 21Shares core XRP Trust ETF (Oct. 19), Bitwise XRP ETF (Oct. 22), Canary Capital XRP ETF (Oct. 23), WisdomTree XRP ETF (Oct. 24) and CoinShares XRP ETF (Oct. 23). The last government shutdown in late 2018 lasted 35 days, the longest in history. Given this, it is difficult to say for how long the current shutdown might last, prompting speculation in the XRP community on the implications if the XRP ETF deadlines were missed by the SEC. Key clarification made Crypto reporter Eleanor Terrett responded to a tweet by XRP enthusiast Chad Steingraber, who cited that the Teucrium XRP ETF was not approved by the SEC directly. This is because the deadline was reached and the SEC didn’t “approve or deny” the listing, adding that it was automatically allowed and that the SEC’s silence indicated compliance. Adding some context here for those asking if this applies to all ETFs, including the spots. The short answer is no. The Teucrium $XRP ETF holds Treasuries, cash, and swap receivables, so it was registered under the 40 Act, meaning the @SECGov didn’t need to actively approve it,… https://t.co/H8EiXVcOHp — Eleanor Terrett (@EleanorTerrett) October 3, 2025 Terrett added context on whether the instance of the Teucrium XRP ETF applies to all ETFs, including the spot ETF applications, to which she answered “no.” The Teucrium XRP ETF, according to…

XRP ETFs Approval Countdown Continues With Key Clarification Made

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • Key clarification made
  • When XRP ETFs?

XRP ETFs countdown remains on for October, with the SEC expected to reveal its decision on six ETF applications.

This week saw a government shutdown as U.S. lawmakers failed to strike a deal on federal funding. As a result, the SEC missed a few deadlines on spot ETF decisions, prompting speculation on what comes next in the markets.

The SEC is expected to rule on Grayscale XRP ETF (Oct. 18), 21Shares core XRP Trust ETF (Oct. 19), Bitwise XRP ETF (Oct. 22), Canary Capital XRP ETF (Oct. 23), WisdomTree XRP ETF (Oct. 24) and CoinShares XRP ETF (Oct. 23).

The last government shutdown in late 2018 lasted 35 days, the longest in history. Given this, it is difficult to say for how long the current shutdown might last, prompting speculation in the XRP community on the implications if the XRP ETF deadlines were missed by the SEC.

Key clarification made

Crypto reporter Eleanor Terrett responded to a tweet by XRP enthusiast Chad Steingraber, who cited that the Teucrium XRP ETF was not approved by the SEC directly. This is because the deadline was reached and the SEC didn’t “approve or deny” the listing, adding that it was automatically allowed and that the SEC’s silence indicated compliance.

Terrett added context on whether the instance of the Teucrium XRP ETF applies to all ETFs, including the spot ETF applications, to which she answered “no.”

The Teucrium XRP ETF, according to Terrett, holds treasuries, cash and swap receivables, so it was registered under the 40 Act, meaning the SEC didn’t need to actively approve it, but just to let it go effective.

When XRP ETFs?

Terrett noted that the SEC also generally lets futures ETFs go effective once the statutory period passes, rather than requiring a new, active approval each time.

Spot ETFs, though, are registered under the 33 Act as commodity trusts and do require explicit SEC approval before launching, Terrett added.

In this light, Terrett speculates that any new spot crypto ETFs, including that of XRP, might not begin trading until the SEC can declare the S‑1s effective, likely after the government shutdown is over and the agency has returned to operating at full capacity.

Source: https://u.today/xrp-etfs-approval-countdown-continues-with-key-clarification-made

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3665
$1.3665$1.3665
+0.73%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09